Truist Securities raised its price target on Cytokinetics, Inc. (NASDAQ: CYTK) to $84 from $70 while maintaining a Buy rating, reflecting updated forecasts following regulatory approval of MYQORZO.
The analyst said the recent approval, which came with a differentiated label, positioned MYQORZO to become a meaningful revenue driver in obstructive hypertrophic cardiomyopathy. Truist updated its model to reflect the product’s commercial potential, now estimating worldwide peak sales for MYQORZO in oHCM of $3.7 billion, compared with a $3.8 billion consensus estimate.
The firm expected a steady launch beginning in early 2026 and said performance should be at least comparable to the launch trajectory of Camzyos. Truist modeled fiscal 2026 aficamten revenue of $106 million, in line with consensus expectations.
Looking further out, the analyst projected worldwide peak adjusted total revenue of $4.6 billion in 2035, the terminal year of its model, slightly above the $4.5 billion consensus estimate. Based on these updates, Truist increased its price target to $84 per share.
